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Abstract 
A 74-year-old woman with extensive lichen planus mucosae (LPM) developed stenotic 
esophagitis that was refractory to intravenous glucocorticosteroids. Esophageal dilatations to 
14 mm width were repeatedly performed without any lasting effect. After introducing oral 
apremilast, she experienced complete clinical remission within the first 4 weeks of treatment. 
Control esophagoscopy confirmed a marked recovery of the esophageal mucosa with no 
recurrence of the former stenosis. Our observation is in line with the case series of Paul et al. 
[J Am Acad Dermatol 2013;68:255–261] who first reported on the benefit of apremilast in 
patients with extensive LPM. Ideally, the effectiveness of apremilast in LPM should be studied 
in a randomized controlled trial. © 2016 The Author(s) 
 Published by S. Karger AG, Basel 
Introduction 
Erosive lichen planus mucosae (LPM) is a severe skin and mucosal disease which can se-
riously hamper nutrition if complications of the pharynx and esophagus are involved, even-
tually leading to deficiency symptoms. Paul et al. [1] reported on a series of 10 patients with 
biopsy-proven LPM who were treated with apremilast 20 mg twice daily. Three patients 
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(30%) showed an improvement of two grades on the Physician Global Assessment scale, but 
all participants experienced significant clinical improvement. 
Case Report 
We are currently treating a 74-year-old woman with extensive LPM. She started devel-
oping genital skin changes at the age of 67 years, which were initially diagnosed as lichen 
sclerosus et atrophicus. Three years later, erosive stomatitis developed, and a mucosal biop-
sy showed the distinct histologic pattern of lichen planus. She has reported difficulties in 
swallowing for the last year. Gastroduodenoscopy confirmed erosive esophagitis and a long 
stenosis starting 20 cm ab ore (fig. 1). 
Immunosuppressive treatment with pulsed intravenous methylprednisolone (125 
methylprednisolone on 3 consecutive days, repeated 4 weeks later) did not show any bene-
ficial effect, and azathioprine had to be ceased due to raised transaminases. Meanwhile, she 
developed a candida superinfection. Esophageal dilatations to 14 mm width were repeatedly 
performed without any lasting effect. 
Having noted the publication of Paul et al. [1], we started treatment with apremilast. On-
ly 4 weeks later, the patient was clinically free of dysphagia, and the erosive stomatitis had 
gone into complete remission (fig. 2). Control esophagoscopy confirmed a marked recovery 
of the esophageal mucosa with no recurrence of the former stenosis but some remaining 
enanthema and increased sensitivity to the mechanical stress caused by the endoscope. 
Our case supports the observation of Paul et al. [1] that apremilast may represent a val-
uable immunomodulatory treatment for LPM. To our knowledge, this is the first report of 
successful application of apremilast in LPM-associated esophagitis, a rare but serious muco-
sal disease. The future will show whether more physicians can confirm our observation. 
Ideally, the effectiveness of apremilast in LPM should be studied in a randomized controlled 
trial. 
Statement of Ethics 
The reported off-label use of apremilast in lichen planus mucosae-associated stenotic 
esophagitis has been conducted according to the recommendations of the Swiss Academy of 
Medical Sciences (www.samw.ch – Ethik – Archiv 2014, 11/06/2014). The patient has given 
her written informed consent. 
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Fig. 1. Esophagogastroscopy before the onset of apremilast treatment shows LPM esophagitis with esopha-
geal stenosis 20 cm ab ore. 
 
 
 
Fig. 2. Control esophagogastroscopy at 4 weeks of apremilast treatment shows no recurrence of the former 
stenosis. 
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